title: Validity of positron emission tomography using fluoro-2-deoxyglucose for the preoperative evaluation of endometrial cancer.
abstract: To clarify the validity of positron emission tomography using fluoro-2-deoxyglucose (FDG-PET) for the preoperative evaluation of endometrial cancer, we analyzed the preoperative FDG-PET images of both primary and metastatic lesions of 30 patients with endometrial cancer, and compared them with computed tomography (CT) and/or magnetic resonance imaging (MRI) images and the results of postoperative pathologic findings. As to the primary lesions, FDG-PET could easily identify the cancer, and the sensitivity was 96.7%, which tended to be higher than that of 83.3% by CT/MRI. As to the evaluation of retroperitoneal lymph node metastasis, FDG-PET could detect none of five cases of lymph node metastatic lesions of up to 0.6 cm in diameter but had higher specificity (100%) compared with CT/MRI (85.7%). The sensitivity of FDG-PET for detection of extrauterine lesions excluding retroperitoneal lymph nodes was 83.3% and was superior to that of CT/MRI (66.7%), although there was no difference in the specificity between the modalities (100%). The diagnostic ability of FDG-PET was limited if used alone, but FDG-PET gave additional information especially with regard to the extrauterine lesions whose significance could not be determined on CT/MRI. However, we also found that FDG-PET could not identify any lymph node metastasis less than 1 cm in diameter; therefore, a negative finding of lymph node metastasis on FDG-PET should not be interpreted as a reason for omitting retroperitoneal lymph node dissection for the precise surgical staging of endometrial cancer.
authors.affiliation: Department of Obstetrics and Gynecology, Yokohama City University School of Medicine, Yokohama, Japan.
authors.forename: R
authors.initials: R
authors.lastname: Suzuki
authors.forename: E
authors.initials: E
authors.lastname: Miyagi
authors.forename: N
authors.initials: N
authors.lastname: Takahashi
authors.forename: A
authors.initials: A
authors.lastname: Sukegawa
authors.forename: A
authors.initials: A
authors.lastname: Suzuki
authors.forename: I
authors.initials: I
authors.lastname: Koike
authors.forename: K
authors.initials: K
authors.lastname: Sugiura
authors.forename: N
authors.initials: N
authors.lastname: Okamoto
authors.forename: T
authors.initials: T
authors.lastname: Inoue
authors.forename: F
authors.initials: F
authors.lastname: Hirahara
mesh_terms: D000328:Adult; D000368:Aged; D016889:Endometrial Neoplasms / Q000000981:diagnostic imaging* / Q000473:pathology; D005260:Female; D005462:Fluorine Radioisotopes; D019788:Fluorodeoxyglucose F18; D006801:Humans; D008207:Lymphatic Metastasis; D008279:Magnetic Resonance Imaging / Q000379:methods; D008875:Middle Aged; D049268:Positron-Emission Tomography / Q000379:methods; D011300:Preoperative Care; D019275:Radiopharmaceuticals; D015203:Reproducibility of Results; D012680:Sensitivity and Specificity; D014057:Tomography, X-Ray Computed / Q000379:methods
chemical_list: D005462:Fluorine Radioisotopes; D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18